tiprankstipranks
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
US Market

Y-Mabs Therapeutics (YMAB) Income Statement

Compare
519 Followers

Y-Mabs Therapeutics Income Statement

Last quarter (Q3 2024), Y-Mabs Therapeutics's total revenue was $18.46M, a decrease of -9.74% from the same quarter last year. In Q3, Y-Mabs Therapeutics's net income was $-7.00M. See Y-Mabs Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 84.82M$ 65.27M$ 34.90M$ 20.75M$ 0.00
Gross Profit
$ 73.40M$ 57.70M$ 32.38M$ 18.55M$ -166.00K
Operating Expenses
$ 99.08M$ 152.51M$ 147.82M$ 138.48M$ 83.00M
Depreciation and Amortization
$ 735.00K$ 839.00K$ 782.00K$ 396.00K$ 166.00K
EBITDA
$ -24.94M$ -94.73M$ -54.49M$ -119.54M$ -82.84M
Operating Income
$ -25.67M$ -94.81M$ -115.43M$ -119.94M$ -83.00M
Other Income/Expenses
$ 4.81M$ -757.00K$ 60.16M$ 598.00K$ 1.98M
Pretax Income
$ -20.87M$ -95.57M$ -55.27M$ -119.34M$ -81.03M
Net Income
$ -21.43M$ -96.33M$ -56.34M$ -118.34M$ -78.89M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -0.49$ -2.20$ -1.30$ -2.95$ -2.24
Diluted EPS
$ -0.49$ -2.20$ -1.30$ -2.95$ -2.24
Weighted Average Shares Outstanding
43.65M 43.70M 43.18M 40.12M 35.18M
Weighted Average Shares Outstanding (Diluted)
43.65M 43.70M 43.18M 40.12M 35.18M
Currency in USD

Y-Mabs Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis